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Previous studieshave shown thatdopamineandgalaninmodulate cholinergic transmission in thehippocampus, but little is knownabout
themechanisms involved and their possible interactions. By using resonance energy transfer techniques in transfectedmammalian cells,
we demonstrated the existence of heteromers between the dopamine D1-like receptors (D1 and D5) and galanin Gal1 , but not Gal2
receptors. Within the D1–Gal1 and D5–Gal1 receptor heteromers, dopamine receptor activation potentiated and dopamine receptor
blockade counteracted MAPK activation induced by stimulation of Gal1 receptors, whereas Gal1 receptor activation or blockade did not
modify D1-like receptor-mediated MAPK activation. Ability of a D1-like receptor antagonist to block galanin-induced MAPK activation
(cross-antagonism) was used as a “biochemical fingerprint” of D1-like–Gal1 receptor heteromers, allowing their identification in the rat
ventral hippocampus. The functional role of D1-like–Gal receptor heteromers was demonstrated in synaptosomes from rat ventral
hippocampus, where galanin facilitated acetylcholine release, but only with costimulation of D1-like receptors. Electrophysiological
experiments in rat ventral hippocampal slices showed that these receptor interactions modulate hippocampal synaptic transmission.
Thus, a D1-like receptor agonist that was ineffective when administered alone turned an inhibitory effect of galanin into an excitatory
effect, an interaction that required cholinergic neurotransmission. Altogether, our results strongly suggest that D1-like–Gal1 receptor
heteromers act as processors that integrate signals of two different neurotransmitters, dopamine and galanin, tomodulate hippocampal
cholinergic neurotransmission.
Introduction
The neuropeptide galanin is widely distributed in the CNS (Me-
lander et al., 1986a,b; Ho¨kfelt et al., 1998; O¨gren et al., 1998),
where it is coreleased with noradrenaline, serotonin, histamine,
and acetylcholine (ACh) (Ho¨kfelt et al., 1998). Particular atten-
tion has been given to the presence of galanin in a population of
cholinergic neurons in the septal nucleus and diagonal band of
Broca, which project to the hippocampal formation (Melander et
al., 1985), because of its possible relevance for learning, memory,
and Alzheimer’s disease (O¨gren et al., 1998; Mitsukawa et al.,
2008). Gal1 and Gal2 receptors are the predominant galanin re-
ceptor subtypes in the brain and, together with the less populated
subtype Gal3, they belong to the G-protein-coupled receptor
(GPCR) family (Branchek et al., 2000). The lack of selective li-
gands and reliable antibodies (Hawes and Picciotto, 2005) has
made it difficult to identify the distribution of Gal1 and Gal2
receptors in the septohippocampal system. Gal1 mRNA is highly
expressed in the septal area, where Gal2 mRNA expression is
moderate and confined to a few scattered neurons (Parker et al.,
1995; O’Donnell et al., 1999). 125I-galanin binding sites in the
ventral hippocampus are significantly reduced after lesions of the
septohippocampal projection, which eliminatesmost cholinergic
input to the ventral hippocampus (Fisone et al., 1987). This pro-
vided clear evidence for the existence of a significant population
of presynaptic hippocampal galanin receptors localized in cho-
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linergic nerve terminals, although the galanin receptor subtype
involved is still a matter of debate (Miller et al., 1997). With
postsynaptic galanin receptors, Gal1 is preferentially expressed in
the ventral hippocampus, CA1, and subiculum, whereas Gal2 is
expressed in the dentate gyrus of both ventral and dorsal hip-
pocampus (O’Donnell et al., 1999).
In vivo studies in rodents with central administration of gala-
nin have suggested that galanin inhibits cholinergic neurotrans-
mission in the ventral hippocampus (Fisone et al., 1987; O¨gren et
al., 1998; Laplante et al., 2004a). Furthermore, central adminis-
tration of galanin leads to cognitive deficits in a variety of tasks
(Crawley, 1996; O¨gren et al., 1998).However, recent postmortem
studies on brains from Alzheimer’s disease patients suggest that
galanin may instead stimulate cholinergic neurotransmission,
which could attenuate the development of Alzheimer’s symp-
toms (Counts et al., 2008; O¨gren et al., 2010).
In addition to galanin, dopamine also plays a key modulatory
role in the septohippocampal cholinergic pathway. Initial studies
showed that dopamine facilitates hippocampal ACh release by
acting on D1-like receptors that are thought to be located in hip-
pocampal cholinergic terminals (Hersi et al., 1995). Of the two
D1-like receptor subtypes, D1 and D5, D5 is the predominant
subtype in the hippocampus (Ciliax et al., 2000) and the onemost
probably involved in the modulation of hippocampal ACh re-
lease (Hersi et al., 2000; Laplante et al., 2004b). In the present
study, we demonstrate that dopamine and galanin work in con-
cert to modulate cholinergic neurotransmission in the ventral
hippocampus and that this modulation can occur via heteromers
between D1 or D5 receptors and Gal1 receptors.
Materials andMethods
Animals. Male Wistar rats (4–7 weeks old) from Harlan Interfauna
Iberica were housed in a temperature- (21  1°C) and humidity-
controlled (55 10%) room with a 12 h light/dark cycle with food and
water ad libitum. Animal procedures were conducted according to stan-
dard ethical guidelines (European Communities Council Directive 86/
609/EEC) and approved by the local (Portuguese or Spanish) ethical
committees. Rats were anesthetized with isoflurane before decapitation.
Cell culture. Human embryonic kidney 293T (HEK-293T) cells were
grown in DMEM supplemented with 2 mM L-glutamine, 100 gml1
sodium pyruvate, 100 units/ml penicillin/streptomycin, and 5% (v/v)
heat-inactivated fetal bovine serum (FBS) (all supplements were from
Invitrogen). Chinese hamster ovary (CHO) cells were cultured in MEM
medium without nucleosides supplemented with 100 units/ml of pen-
icillin/streptomycin and 10% (v/v) heat-inactivated FBS. HEK-293T and
CHO cells were maintained at 37°C in a humidified atmosphere of 5%
CO2 and were passaged when they were 80–90% confluent, i.e., approx-
imately twice a week.
Fusion proteins and expression vectors. The cDNAs for D1, D5,
Gal1,Gal2, cannabinoid CB1, and serotonin 5HT2B receptors cloned into
pcDNA3.1 were amplified without their stop codons using sense and
antisense primers harboring unique EcoRI and BamHI sites to clone D1,
D5, and 5HT2B receptors and EcoRV and KpnI sites to clone Gal2 recep-
tors in the Renilla luciferase (Rluc) vector, or EcoRI and BamHI to clone
D1, D5, and CB1 receptors and EcoRI andKpnI to clone the Gal1 receptor
in the enhanced yellow fluorescent protein (EYFP) vector. The ampli-
fied fragments were subcloned to be in-frame into restriction sites of
pcDNA3.1-Rluc (Renilla luciferase; Clontech) or pEYFP-N1 (Clontech)
vectors resulting in the plasmids D1-Rluc, D1-YFP, D5-Rluc, D5-YFP,
Gal1-YFP, andGal2-Rluc. Expression of constructswas tested by confocal
microscopy, and the receptor functionality by ERK1/2 phosphorylation
(see Results). The cDNA encoding the C terminus of the rat D1 or D5
receptors (D1CT and D5CT, respectively) were amplified from Rat Brain
QUICK-Clone cDNA (Clontech) by PCR using the following primers:
D1-CT1012F (CAGAAGGCGTTCTCAACC) andD1-CT1321R (AGT
GGA ATG CTG TCC ACT) or D5-CT1051F (CCC ATC ATC TAT GCC
TTTAATGCAGACTTC) andD5-CT1425R (AGCAGTTTTATCGAA
ACA ATT GGG GGT GAG). The cDNA encoding D1CT or D5CT were
subcloned into theBamHI/EcoRI sites of pGEX-4T-1 (GEHealthcare). A
GST fusion protein containing the C terminus of the rat D1 or D5 recep-
tors (GST-D1CT and GST-D5CT, respectively) were generated corre-
sponding to amino acid residues 227–335 of the rat D1 receptor and
amino acid residues 358–475 of the rat D5 receptor, respectively. Bacte-
rial BL21 (DE3) cells with pGEX-4T-1/Drd5CT plasmid were grown
overnight in imMedia medium (Invitrogen) using ampicillin selection.
Protein production was induced with 0.5 mM isopropyl--D-
thiogalactopyranoside (Sigma) at 20°C for 18 h. Bacteria were harvested
by centrifugation at 7,500  g for 15 min at 4°C, and the pellet was
suspended in cold PBS buffer with 1 mM PMSF and a protease inhibitor
mixture (Roche). Cells were lysed by sonication, and the lysate was incu-
bated for 1 h with 1% Triton X-100 and centrifuged at 18,000 g for 10
min at 4°C. The supernatant was collected for purification of GST fusion
protein. Purification of fusion proteins was performed using the Gluta-
thione Sepharose 4B bead matrix (GE Healthcare) as described by the
manufacturer.
Transient transfection and protein determination. HEK-293T or CHO
cells growing in 35-mm-diameter wells of six-well plates were transiently
transfected with the corresponding fusion protein cDNA by the ramified
polyethylenimine (PEI; Sigma) method. Cells were incubated (4 h) with
the corresponding cDNA together with ramified PEI (5 ml/mg cDNA of
10mM PEI) and 150mMNaCl in a serum-starvedmedium. After 4 h, the
medium was changed to a fresh complete culture medium. Forty-eight
hours after transfection, cells were washed twice in quick succession in
HBSS [containing the following (in mM): 137 NaCl, 5 KCl, 0.34
Na2HPO4 12 H2O, 0.44 KH2PO4, 1.26 CaCl2 2 H2O, 0.4 MgSO4
7 H2O, 0.5 MgCl2, 10 HEPES, pH 7.4], supplemented with 0.1% glucose
(w/v), detached by gently pipetting, and resuspended in the same buffer.
To control the cell number, sample protein concentration was deter-
mined using a Bradford assay kit (Bio-Rad) using bovine serum albumin
(BSA) dilutions as standards. HEK-293T cell suspension (20 g of pro-
tein) was distributed into 96-well microplates; black plates with a trans-
parent bottom (Porvair) were used for fluorescence determinations,
whereas white opaque plates (Sigma) were used for bioluminescence
resonance energy transfer (BRET) experiments.
BRET assays. HEK-293T cells were transiently cotransfected with the
indicated amounts of plasmid cDNAs corresponding to the indicated
fusion proteins (see corresponding figure legends). To quantify fluores-
cence proteins, cells (20 g protein) were distributed in 96-well micro-
plates (black plates with a transparent bottom) and fluorescencewas read
in a Fluo Star Optima fluorimeter (BMG Lab Technologies) equipped
with a high-energy xenon flash lamp, using a 10 nmbandwidth excitation
filter at 400 nm reading. Receptor-fluorescence expression was deter-
mined as fluorescence of the sample minus the fluorescence of cells ex-
pressing receptor-Rluc alone. For BRETmeasurements, the equivalent of
20g of cell suspension was distributed in 96-well microplates (Corning
3600, white plates; Sigma) and 5 M coelenterazine H (Invitrogen) was
added. After 1 min of adding coelenterazine H, readings were collected
using a Mithras LB 940 (Berthold), which allows the integration of the
signals detected in the short-wavelength filter at 485 nm (440–500 nm)
and the long-wavelength filter at 530 nm (510–590 nm). To quantify
receptor-Rluc expression, luminescence readings were performed after
10 min of adding 5 M coelenterazine H. Cells expressing BRET donors
alone were used to determine background. The net BRET is defined as
[(long-wavelength emission)/(short-wavelength emission)]Cf, where
Cf corresponds to [(long-wavelength emission)/(short-wavelength emis-
sion)] for the Rluc construct expressed alone in the same experiment.
Curves were fitted using a nonlinear regression equation and assuming a
single phase (GraphPadPrism software). BRET is expressed asmili BRET
units (mBU: 1000 net BRET).
Immunocytochemistry.After 48 h of transfection, HEK-292T cells were
fixed in 4% paraformaldehyde for 15min and washed with PBS contain-
ing 20 mM glycine (buffer A) to quench the aldehyde groups. Cells were
permeabilized with buffer A containing 0.05% Triton X-100 for 5 min
and then were treated with PBS containing 1% bovine serum albumin.
After 1 h at room temperature, protein-Rlucwas labeledwith the primary
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mouse monoclonal anti-Rluc antibody (1/100; Millipore Bioscience Re-
search Reagents) for 1 h, washed, and stained with the secondary anti-
body Cy3 Donkey anti-mouse (1/200; Jackson ImmunoResearch).
Protein-YFP was detected by its fluorescence properties. The slides were
rinsed several times and mounted with a medium suitable for immuno-
fluorescence (30%Mowiol; Calbiochem). The samples were observed in
a Leica SP2 confocal microscope (Leica Microsystems).
Pull-down assay.HEK-293T cells were collected after 48 h of transfec-
tion with 25 g Gal1-YFP, Gal2-YFP, or pEYFP-N1 plasmid (control)
and extracted in cell extraction buffer (10mMTris, pH 7.4, 100mMNaCl,
1mMEDTA, 1mMEGTA, 1mMNaF, 20mMNa4P2O7, 2mMNa3VO4, 1%
Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate) with 1 mM
PMSF and a protease inhibitor mixture (Roche) for 30 min on ice. The
cell extracts were centrifuged at 16,000  g for 10 min at 4°C, and the
supernatant was used for pull-down experiments. Pull-down experi-
ments were performed by incubating cell extracts (135 relative fluores-
cence units per 800 l) with 50 g GST-D1CT, GST-D5CT, or GST for
2 h with constant rotation at 4°C. Then, 30 l Glutathione Sepharose 4B
beads were added, and incubation was prolonged for 1 h. The beads were
then washed four times with cold wash buffer (TBS, 0.1% Triton X-100,
and protease inhibitor mixture). Subsequently, 50 l of elution buffer
(10 mM reduced glutathione in 50 mM Tris-HCl, pH 8.0) was added to
each sample and kept for 10 min at room temperature. Fluorescence in
the eluted solution was measured with SpectraMaxM5microplate read-
ers (Molecular Devices) using 514 nmwavelength excitation and 596 nm
wavelength emission filters. Differences in relative fluorescence units
among the different groups were statistically analyzed with repeated-
measures ANOVA with Bonferroni’s correction.
ERK phosphorylation assay. Transfected CHO cells were cultured in
serum-free medium for 16 h before the addition of any agent. For assays
in hippocampal slices, rat brains were rapidly removed and placed in
ice-cold oxygenated (95%O2/5%CO2) Krebs-HCO3
 buffer [containing
(in mM) 124 NaCl, 4 KCl, 1.25 NaH2PO4, 1.5 MgCl2, 1.5 CaCl2, 10
glucose, and 26 NaHCO3, pH 7.4]. The brains were sliced perpendicu-
larly to the long axis of the hippocampus at 4°C. Slices (400 m thick)
were kept at 4°C in Krebs-HCO3
 buffer during the dissection. Each
hippocampal slice was transferred into an incubation tube containing 1
ml of ice-cold Krebs-HCO3
 buffer [containing (inmM) 124NaCl, 4 KCl,
1.25 NaH2PO4, 1.5 MgCl2, 1.5 CaCl2, 10 glucose, and 26 NaHCO3]. The
temperature was raised to 23°C, and after 30 min the medium was re-
placed by 2 ml of fresh Krebs-HCO3
 buffer (23°C) with similar compo-
sition. The slices were incubated under constant oxygenation (95%
O2/5% CO2) at 30°C for 4–5 h in an Eppendorf-5 Prime Thermomixer.
The medium was replaced by 200 l of fresh Krebs-HCO3
 buffer and
incubated for 30min before the addition of any agent. Cells or slices were
treated or not with the indicated ligand for the indicated time and were
rinsed with ice-cold PBS and lysed by the addition of 500 l of ice-cold
lysis buffer (50 mM Tris-HCl, pH 7.4, 50 mM NaF, 150 mM NaCl, 45 mM
-glycerophosphate, 1% Triton X-100, 20 M phenyl-arsine oxide, 0.4
mM NaVO4, and protease inhibitor mixture). The cellular debris was
removed by centrifugation at 13,000 g for 5min at 4°C, and the protein
was quantified by the bicinchoninic acid method using bovine serum
albumin dilutions as standard. To determine the level of ERK1/2 phos-
phorylation, equivalent amounts of protein (10 g) were separated by
electrophoresis on a denaturing 7.5% SDS-polyacrylamide gel and trans-
ferred onto PVDF-fluorescence membranes. Odyssey blocking buffer
(LI-CORBiosciences)was then added, and themembranewas rocked for
90 min. The membranes were then probed with a mixture of a mouse
anti-phospho-ERK1/2 antibody (1:2500; Sigma) and rabbit anti-ERK1/2
antibody that recognizes both phosphorylated and nonphosphorylated
ERK1/2 (1:40,000; Sigma) for 2–3 h. Bands were visualized by the addi-
tion of a mixture of IRDye 800 (anti-mouse) antibody (1:10,000; Sigma)
and IRDye 680 (anti-rabbit) antibody (1:10,000; Sigma) for 1 h and
scanned by the Odyssey infrared scanner (LI-COR Biosciences). Bands
densities were quantified using the scanner software exported to Excel
(Microsoft). The level of phosphorylated ERK1/2 isoforms was normal-
ized for differences in loading using the total ERK protein band intensi-
ties. Statistical differences between the different groups were analyzed by
one-way ANOVA with Bonferroni’s correction.
[3H]Ach release from hippocampal synaptosomes. The synaptosomal
fraction was prepared according to routine (Vaz et al., 2008). Briefly,
after decapitation under halothane anesthesia, each brain was rapidly
removed into ice-cold continuously oxygenated (95%O2/5% CO2) arti-
ficial CSF (aCSF) containing the following (in mM): 124 NaCl, 3 KCl, 1.2
NaH2PO4, 25 NaHCO3, 2 CaCl2, 1MgSO4, and 10 glucose, pH 7.40. The
whole hippocampus was dissected out free of the subiculum or enthori-
nal cortex areas and the ventral part, i.e., the portion lying in the temporal
part of the brain, was isolated from the dorsal one (the portion lying just
behind the septum) by a cutmade perpendicularly to the long hippocam-
pal axis. The ventral hippocampi were homogenized in an ice-cold isos-
motic sucrose solution (0.32 M, containing 1 mM EDTA, 1 mg/ml bovine
serum albumin, and 10 mM HEPES, pH 7.4) and centrifuged at 3,000
g for 10 min; the supernatant was centrifuged again at 14,000 g for 12
min. The whole procedure was conducted at 4°C. The pellet was resus-
pended in 45% Percoll in Krebs–Henseleit–Ringer solution containing
(in mM) 140 NaCl, 1 EDTA, 10 HEPES, 5 KCl, and 5 glucose, and was
centrifuged 14,000  g for 2 min. The synaptosomal fraction corre-
sponds to the top buoyant layer and was collected from the tube. Percoll
was removed by two washes with a KHR solution; synaptosomes were
then kept on ice and used within 3 h. The synaptosomes were loaded for
20min at 37°C, with [methyl- 3H] choline chloride (10Ci/ml, 122 nM).
Hemicholinium-3 (10 M) was present in all solutions up the end of the
experiments to prevent choline uptake. Synaptosomes were then layered
overWhatmanGF/C filters and superfused (flow rate, 0.8ml/min; cham-
ber volume, 90l) with gassed aCSF. After a 30 min washout period, the
effluent was collected (release period) in 2 min fractions for 36 min. The
synaptosomes were stimulated during 2 min with 20 mM K (isomolar
substitution of Nawith K in the perfusion buffer) at the 5th and 23rd
minutes after starting sample collection (S1 and S2, respectively). The
tested drugs were added to the superfusion medium at the 17th minute,
therefore before S2, and remained in the bath up to the end of the exper-
iments. When we evaluated the changes of galanin effect by the D1-like
receptor agonist SKF 38393, this was applied at the beginning of the
washout period, and therefore it was present during S1 and S2 in both test
and control chambers, whereas galanin was added before S2 in the test
chambers. A “mirror” experiment was also performed to evaluate
changes of the effect of SFK 38393 effect by galanin; in this case the
neuropeptide was applied at the beginning of the washout period, being
therefore present during S1 and S2 in both test and control chambers,
whereas SKF 38393 was added before S2 in the test chambers. At the end
of each experiment, aliquots (500 l) of each sample as well as the filters
from each superfusion chamber were analyzed by liquid scintillation
counting. The fractional release was expressed in terms of the per-
centage of total radioactivity present in the preparation at the beginning
of the collection of each sample. The amount of radioactivity released by
each pulse of K (S1 and S2) was calculated by integration of the area of
the peak after subtraction of the estimated basal tritium release. In each
experiment, two synaptosome-loaded chambers were used as control
chambers, the others being used as test chambers. In the test chambers,
the test drugwas added to the perfusion solution before S2, and the S2/S1
ratios in control and test conditions were calculated. The effect of the
drug on the K-evoked tritium release was expressed as percentage of
change of the S2/S1 ratios in test conditions compared to the S2/S1 ratios
in control conditions in the same experiments (i.e., with the same pool of
synaptosomes).When present during S1 and S2, neither galanin nor SKF
38393 significantly (p  0.05, Student’s t test) altered the S2/S1 ratio as
compared with the S2/S1 ratio obtained in the absence of these drugs.
The values presented are the mean  SEM of n experiments. For com-
parisons, statistical significance was assessed with Student’s t test using
GraphPad Software (Prism, version 4.02 for Windows).
Field EPSP recordings fromhippocampal slices.After decapitationunder
halothane anesthesia, the hippocampus was dissected out of the brain on
ice-cold continuously oxygenated (95% O2/5% CO2) aCSF as described
above. Ventral and dorsal hippocampal slices (400m thick, cut perpen-
dicularly to the long axis of the hippocampus) were allowed to recover
functionally and energetically for at least 1 h in a resting chamber filled
with continuously oxygenated (95%O2/5%CO2) aCSF at room temper-
ature (22–25°C). After recovering, slices were transferred to a recording
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chamber (1 ml plus 5 ml dead volume) for submerged slices, and were
continuously superfused (3 ml/min) at 32°C with oxygenated aCSF; the
drugs were added to this superfusion solution. To minimize peptide lost
resulting from binding to the perfusion system, all of the system was
superfused with 0.1 mg/ml BSA before starting any experiment. Field
EPSPs (fEPSPs) were recorded according to routine (Dio´genes at al.,
2004) through an extracellular microelectrode (4 MNaCl, 2–6M resis-
tance) placed in the stratum radiatumof the CA1 area. Stimulation (rect-
angular 0.1 ms pulses, once every 15 s) was delivered through a
concentric electrode placed on the Schaffer collateral–commissural fib-
bers in the stratum radiatum near the CA3–CA1 border. The intensity of
stimulus (80–200A)was initially adjusted to obtain a large fEPSP slope
with a minimum population spike contamination. Recordings were ob-
tainedwith anAxoclamp2B amplifier and digitized (MolecularDevices).
Individual responses were monitored, and averages of eight consecutive
responses were continuously stored on a personal computer with the
LTP program (Anderson and Collingridge, 2001). Data are expressed as
the mean  SEM from n number of slices. To allow comparisons be-
tween different experiments, slope values were normalized, taking as
100% of the averaged of the five values obtained immediately before
applying the test compound. The significance of differences between the
mean values obtained in test and control conditions was evaluated by
Student’s t test. For multiple comparisons, the one-way ANOVA fol-
lowed by the Bonferroni correction was used.
Drugs. Galanin was from Bachem. (R)-()-7-chloro-8-hydroxy-3-
methyl-1-phenyl-2,3,4,5-te trahydro-1H-3-benzazepine hydrochloride
(SCH 23390), ()-6-chloro-2,3,4,5-tetrahydro-1-phenyl-1H-3-benzaz-
epine hydrobromide (SKF 81297), ()-1-phenyl-2,3,4,5-tetrahydro-
(1H)-3-benzazepine-7,8-diol hydrobromide (SKF 38393), and
galanin (1–13)-Pro-Pro-(Ala-Leu-)2Ala amide (M40) were from Tocris
Cookson. BSA and atropine were from Sigma.
Galaninwas supplied as a powder that was resus-
pended in TBS buffer (50 mM Tris-base, 150mM
NaCl, pH 7.60) in a 0.5 mM concentration stock
solution. SCH 23390 (10 mM), SKF 38393 (10
mM), and atropine (50mM) stock solutions were
prepared in water. Aliquots of these stock solu-
tions were kept frozen at20°C until use.
Results
D1 and D5 receptors form heteromers
with Gal1 receptors but not with Gal2
receptors
We first looked for a molecular interac-
tion between dopamine D1-like and Gal1
receptors using an in vitro energy transfer
assay. First, receptors were cloned as fu-
sion proteins competent for energy trans-
fer experiments. To ensure the fusion
proteins trafficked to the correct location
in the cell, we performed immunofluores-
cence experiments in transfected HEK
cells. All fusion proteins were found to
properly express and localize at the
plasma membrane (Fig. 1a). Fusion of
Rluc orYFPdid notmodify receptor func-
tion, as determined by ERK1/2 phosphor-
ylation assays (data not shown). Next, we
examined whether D1 or D5 and Gal1 re-
ceptors form heteromers using the BRET
technique. The BRET technique allows
real-time detection of two proteins in
close proximity in living cells. BRETmea-
surements were performed in transiently
cotransfected HEK cells using a constant
amount of cDNA, corresponding to D1-
Rluc or D5-Rluc receptors, and increasing
amounts of cDNA, corresponding to Gal1-YFP receptors. A pos-
itive and saturable BRET signal was obtained in cells coexpressing
D1-Rluc and Gal1-YFP receptors, with a BRETmax value of 47  4
mBU and a BRET50 value of 7  2, or in cells coexpressing D5-
Rluc and Gal1-YFP receptors, with a BRETmax value of 71  3
mBU and a BRET50 value of 6 1 (Fig. 1b), indicating that both
D1 and D5 receptors formed heteromers with Gal1 receptors. As
negative controls we first used cells cotransfected with a constant
amount of cDNA corresponding to 5HT2B-Rluc and increasing
amounts of cDNA corresponding toGal1-YFP receptors. Second,
we also used cells cotransfected with a constant amount of cDNA
corresponding to D1-Rluc or D5-Rluc and increasing amounts of
cDNA corresponding to CB1-YFP receptors. Only a small and
linear BRET was detected (Fig. 1b), indicating that the saturable
BRET between D1 or D5 and Gal1 represented a true complex.
Since D1-like and Gal1 receptors can form heteromers, we
sought to determine whether D1-likeand Gal2 receptors could
also form heteromers. Using confocal microscopy, we confirmed
expression, proper trafficking of receptors, and colocalization
between D1-YFP and Gal2-Rluc receptors and between D5-YFP
and Gal2-Rluc receptors (Fig. 1a). When we performed BRET
experiments, however, we obtained a linear nonspecific BRET
signal in cells expressing a constant amount of Gal2-Rluc and
increasing amounts of D1-YFP or D5-YFP receptors (Fig. 1c),
suggesting that the two pairs of receptors are not able to form
heteromers. Therefore, the results indicate that D1-like receptors
Figure 1. D1–Gal1 and D5–Gal1 receptor heteromers in living cells. a, Confocal microscopy images of cells expressing (top to
bottom)D5-Rluc (0.6gplasmid) andGal1-YFP (1gplasmid), Gal2-Rluc (0.5gplasmid) andD5-YFP receptors (1gplasmid),
D1-Rluc (0.5g plasmid) and Gal1-YFP (1g plasmid), and Gal2-Rluc (0.5g plasmid) and D1-YFP (1.3g plasmid) receptors.
Proteins were identified by fluorescence or by immunocytochemistry. D5-Rluc, D1-Rluc, or Gal2-Rluc receptor immunoreactivity is
shown in red; Gal1-YFP, D5-YFP, or D1-YFP receptor fluorescence in shown in green; and colocalization is shown in yellow. Scale
bars, 5m.b, BRETexperimentswereperformedwith cells coexpressingD5-Rluc (400ngplasmid; red) orD1-Rluc (300ngplasmid;
blue) and Gal1-YFP receptors (0.4 to 7g plasmid), Gal2-Rluc (300 ng plasmid) and D5-YFP receptors (0.5 to 5g plasmid; green)
or D1-YFP receptors (0.5 to 4 g plasmid; purple), or, as negative controls, D5-Rluc (600 ng plasmid; gray) or D1-Rluc (500 ng
plasmid; orange) and CB1-YFP receptors (0.5 to 7g plasmid) or 5HT2B-Rluc (1g plasmid) and Gal1-YFP receptors (0.5 to 5g
plasmid) (black). Both fluorescence and luminescence of each sample were measured before every experiment to confirm similar
donor expressions (about 150,000 luminescent units) while monitoring the increase acceptor expression (10,000–70,000 fluo-
rescent units). The relative amount of BRET is given as the ratio between the fluorescence of the acceptor minus the fluorescence
detected in cells expressing only the donor and the luciferase activity of the donor. BRET data are expressed as the mean SD of
4–16 different experiments grouped as a function of the amount of BRET acceptor. At the top, a scheme corresponding to a BRET
assay is shown.
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show a preference for forming receptor heteromers with Gal1
receptors.
D1 and D5 receptors compete for the samemolecular
determinants of Gal1 receptors
Previous studies have shown that the C termini of D1 and D5
receptors are selectively involved in the formation of heteromers
with the ligand-gated ion channels of NMDA and GABAA recep-
tors (Liu et al., 2000; Lee et al., 2002). We, therefore, reasoned
that these same regions might interact with Gal1 receptors. We
constructed plasmids expressing the C-terminal part of the D1
and D5 receptors fused to GST protein (GST-D1CT and GST-
D5CT, respectively). We produced this protein in Escherichia coli
and then added it to lysates fromHEK-293T cells transfectedwith
either Gal1-YFP or Gal2-YFP receptors. Using Sepharose beads
coated with glutathione, we precipitated GST-D5CT. With anal-
ysis of fluorescence, we found that the GST-D5CT fusion protein,
but not GST alone, pulled down Gal1-YFP receptors, but not
Gal2-YFP receptors, as demonstrated by a significant increase in
fluorescence in the samples from cells expressingGal1-YFP, com-
pared with samples from cells expressing YFP alone (Fig. 2a).
When we tried the same experiments with GST-D1CT, we were
unable to pull down Gal1-YFP or Gal2-YFP (Fig. 2b). In view of
the very similar results obtained in BRET experiments with the
selective heteromerization of both D1 and D5 receptors with Gal1
but not Gal2 receptors, these results suggest that additional re-
gions outside of the C terminus play a role in forming heteromers
and that there are differences between D1 and D5 receptors in the
regions involved in heteromerization with Gal1 receptors. BRET
competition experiments were then performed to determine
whether Gal1 receptors use the same molecular determinants to
heteromerize with D1 and D5 receptors. BRET was measured in
cells coexpressing D1-Rluc and Gal1-YFP receptors (to give ap-
proximately BRETmax values) with increasing amounts of D5 re-
ceptors. The BRET signal decreased to very low values in the
presence of increasing amounts of D5 receptors, with a complex
dose–response competition curve (Fig. 3a). Because the D1–Gal1
heteromer is disrupted by adding D5 receptor, D1 and D5 recep-
tors must share a similar interaction surface on the Gal1 protein.
To further support this hypothesis, a BRET saturation curve was
performed in cells transfected with a constant amount of cDNA
for the D1-Rluc receptor, with increasing amounts of cDNA for
the Gal1-YFP receptor and with a constant amount of cDNA for
D5 receptors. Under these conditions, there was a very significant
decrease in BRETmax values (23 1 vs. 47 4 mBU; p 0.001),
but not BRET50 values (9 2 vs. 7 2), compared to the BRET
saturation curve in the absence of D5 receptors (Fig. 3b), strongly
suggesting that D1 and D5 receptors compete for the same region
of Gal1 receptors.
Functional characteristics of D1–Gal1 and D5–Gal1 receptor
heteromers
To investigate whether D1-like receptors can modify Gal1 recep-
tor function, and vice versa, we measured changes in ERK1/2
phosphorylation in the presence or absence of D1-like and Gal1
receptor agonists and/or antagonists. First, the D1-like receptor
agonist SKF 81297 (50 nM) time-dependently induced ERK1/2
phosphorylation in cells expressing D1 or D5 receptors, whereas
Figure 2. Role of the C-terminal domains of D1 and D5 receptors in heteromerization with
Gal1 receptor. a, b, Extracts from cells transfected with either Gal1-YFP or Gal2-YFP receptors or
justwith YFP (seeMaterials andMethods)were incubatedwith GST-D5CT orwith just GST (a) or
GST-D1CT, GST-D5CT, or with just GST (b). The results of pull-down experiments (see Materials
andMethods) were analyzed bymeasuring fluorescence. Results are expressed as themean
SEM (3 independent experimentswith 3 replicates) of relative fluorescence units (RFUs); **p
0.01 (significantly different compared to the pull down of YFP with GST-D5CT);
###p 0.001
(significantly different compared to the pull down of Gal1-YFP with GST; repeated-measures
ANOVA with Bonferroni’s correction).
Figure 3. D1 and D5 receptors compete for binding to Gal1 receptors.a,b, BRET experiments
were performedwith cells coexpressingD1-Rluc (300 ngplasmid) andGal1-YFP receptors (4g
plasmid) and increasing amounts of D5 receptors (0 to 5.5g plasmid) (a) or D1-Rluc (300 ng
plasmid), Gal1-YFP (0.3 to 5 g plasmid), and D5 receptors (1.5 g plasmid) (b). In a, no
significant variation in luminescence caused by D1-Rluc receptors (about 150,000 luminescent
units) or fluorescence caused by Gal1-YFP receptors (about 10,000–70,000 fluorescent units)
was observed by increasing D5 receptor expression. In b, similar luminescence attributable to
D1-Rluc or fluorescence attributable to Gal1-YFP receptors was obtained in the absence or pres-
ence of D5 receptors. The relative amount of BRET is given as the ratio between the fluorescence
of the acceptor minus the fluorescence detected in cells expressing only the donor and the
luciferase activity of the donor. BRET data are expressed as the mean SD of 4–16 different
experiments grouped as a function of the amount of BRET acceptor. The dashed curve repre-
sentsBRET saturation curveobtainedwith theD1-Rluc receptor and increasingamounts of cDNA
for the Gal1-YFP receptor in the absence of D5 receptors shown in Figure 1.
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galanin (100 nM) time-dependently induced ERK1/2 phosphor-
ylation in cells expressing Gal1 receptors (Fig. 4a). In cells ex-
pressing both D5 and Gal1 receptors (Fig. 4b,c) or D1 and Gal1
(Fig. 4d,e) receptors, SKF 81297-induced dose–response curves
were not significantly modified by the presence of galanin (100
nM) (Fig. 4b,d). EC50 values in cells expressing both D5 and Gal1
receptorswere 17 2nMand 23 3nM in
the absence and presence of galanin, re-
spectively (nonpaired t test, not signifi-
cant; n  5 in both groups). In cells
expressing both D1 and Gal1 receptors,
EC50 values were 7 1 nM and 11 1 nM
in the absence and presence of galanin,
respectively (nonpaired t test, not signifi-
cant; n 5 in both groups). On the other
hand, galanin-induced dose–response
curves were significantly shifted to the left
in the presence of SKF 81297 (50 nM) (Fig.
4c,e). EC50 values were 17.1  0.7 nM in
the absence of SKF 81297 and 4.8  0.6
nM in the presence of SKF 81297 in cells
expressing both D5 and Gal1 receptors
(nonpaired t test, p 0.001; n 4 in both
groups). EC50 values in cells expressing
both D1 and Gal1 receptors were 21  2
nM in the absence of SKF 81297 and 6 1
nM in the presence of SKF 81297 (non-
paired t test, p  0.001; n  4 in both
groups). These results demonstrate that
D1-like receptor agonist activation facili-
tates Gal1 receptor-mediated MAPK sig-
naling, whereas the reverse is not true,
since no significant functional effects were
observed in the SKF 81297-induced dose–
response curves with galanin. Impor-
tantly, in cells expressing both D1 and
Gal2 receptors or D5 and Gal2 receptors,
galanin-induced dose–response curves
were not significantly modified by the
presence of SKF 81297 (Fig. 5), suggesting
that the enhancement of Gal1 receptor-
mediated MAPK signaling by D1-like re-
ceptor agonist activation is a biochemical
property of D1–Gal1 and D5–Gal1 recep-
tor heteromers.
Next, we examined the effect of hetero-
mer formation on antagonist-modulation
of agonist-induced ERK1/2 phosphoryla-
tion. TheD1-like receptor antagonist SCH
23390 (10 M) was able to block ERK1/2
phosphorylation caused by SKF 81297
in cells expressing D1 or D5 receptors,
whereas the putative nonselective galanin
receptor antagonist M40 (10M) blocked
galanin-induced ERK1/2 phosphoryla-
tion in cells expressingGal1 receptors (Fig.
6a). It is important to mention that M40,
as well as other galanin-like peptides, has
been shown to act as full agonists in some
cell lines, although they are clearly antag-
onists in vivo (Lang et al., 2007). In our
hands, M40 behaved as a galanin receptor
antagonist, as evidenced by the complete
reversion of galanin-induced signaling. In addition, we estab-
lished that in cells expressing only D1 or D5 receptors, signaling
induced by the D1-like receptor agonist SKF 81297 was not mod-
ified by the presence of M40, and in cells expressing only Gal1,
signaling induced by galanin was not altered by addition of SCH
23390 (Fig. 6a). In cells coexpressing both D5 and Gal1 receptors
Figure 4. Cross talk between D1-like receptors and Gal1 receptors on ERK1/2 phosphorylation in transfected cells. a, Cells
transfectedwith the cDNA corresponding to D5 (1.5g, black), D1 (1.2g, white), or Gal1 (2g, gray) receptors were stimulated
for the indicated timeswith 50 nM (black) or 70 nM (white) of the D1-like receptor agonist SKF 81297 orwith 100 nM galanin (gray).
ERK1/2 phosphorylation was determined as indicated in Materials and Methods. The immunoreactive bands from three to five
experimentswere quantified and the values represent themean SEMof the percentage of phosphorylation relative to the basal
levels found in untreated cells; *p 0.05; ***p 0.001 (significantly different compared to the results obtained after 1 min of
agonist exposure; one-way ANOVAwith Bonferroni’s correction).b–e, Cells cotransfectedwith the cDNA corresponding to D5 (1.3
g) and Gal1 (1.8g) receptors (b, c) or D1 (1g) and Gal1 (1.8g) receptors (d, e) were treated for 5 min with the indicated
concentrations of the D1-like receptor agonist SKF 81297 in the absence (circles) or in the presence (triangles) of 100 nM galanin (b,
d) orwith the indicated concentrationsof galanin in absence (circles) or presence (triangles) of 50nM (c) or 70nMSKF81297 (d). The
immunoreactive bands from four independent experiments were quantified and the values represent the mean SEM of phos-
phorylation (arbitrary units) minus the basal levels found in SKF 81297- (b, d) or galanin-untreated (c, e) cells.
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(Fig. 6b) or both D1 and Gal1 receptors
(Fig. 6c), D1-like receptor-mediated
ERK1/2 phosphorylation could be
blocked by SCH 23390 but not by M40.
However, galanin-induced ERK1/2 phos-
phorylation was counteracted by both
M40 and SCH 23390 (Fig. 6b,c). This is a
clear example of unidirectional cross-
antagonism in a receptor heteromer (Car-
riba et al., 2007; Ferrada et al., 2009;
Navarro et al., 2010). Since, by definition,
an antagonist is not able to induce intra-
cellular signaling, the more straightfor-
ward way to explain the effect of D1-like
receptor antagonist on Gal1 receptor ac-
tivation is through a direct protein-
protein interaction between both receptors.
D1-like–Gal1 receptor heteromers are
expressed in the rat ventral
hippocampus
In view of the cross-antagonism clearly ob-
served in the transfected cells, we decided to
use a similar approach to seek biochemical
evidence (“biochemical fingerprint”) for
the existence of D1-like–Gal1 receptor het-
eromers in the brain (Ferre´ et al., 2009).
Therefore, to test whether D1–Gal1 or D5–
Gal1 receptor heteromers exist in the brain,
we isolated rat ventral and dorsal hip-
pocampal slices and compared the ability of
the D1-like receptor antagonist SCH 23390
to block the effect of galanin on ERK1/2
phosphorylation.Sliceswere incubatedwith
galanin in the absence or in the presence of
either SCH 23390 or the galanin receptor
antagonist M40. In the ventral hippocam-
pus, the results reproduced the cross-anta-
gonism found in transfected cells (Fig. 7).
ERK1/2 phosphorylation induced by gala-
nin (300 nM) was not blocked only by M40
(10M), but also by SCH23390 (10M). In
contrast, in dorsal hippocampus slices,
SCH23390 (10M) failed to antagonize the
effect of galanin (Fig. 7). These results pro-
vide strong evidence for the existence ofD1-
like–Gal1 receptor heteromers in the ventral
hippocampus.
The role of D1-like and Gal1 receptor
coactivation on K-induced [3H]ACh
release in synaptosomes from rat
ventral hippocampus
Having established that D1-like–Gal1 re-
ceptor heteromers occur in the ventral
hippocampus, we looked for their func-
tional role by first analyzing the effect of a D1-like agonist and
galanin on K-induced [3H]ACh release in isolated synapto-
somes from rat ventral hippocampus. The D1-like receptor ago-
nists SKF 81297 and SKF 38393 have a similar affinity for D1 and
D5 receptors. The major difference between the two agonists is a
significantly higher selectivity for D1 versus dopamine D2 recep-
tors and D1 versus serotonin 5-HT2A receptors of SKF 38393
compared to SKF 81297 (Seeman and Van Tol, 1994; Neumeyer
et al., 2003). Since selectivity was a major concern when dealing
with hippocampal tissue, we decided to shift to SKF 38393 as the
D1-like receptor agonist in the studies of ACh release in synapto-
somes and the electrophysiological studies in slices. Neither gala-
nin, at low nanomolar concentrations (30–100 nM) in the range
used by Wang et al. (1999) in rat cortical slices and cortical syn-
Figure 5. Lack of cross talk between D1-like receptors and Gal2 receptors on ERK1/2 phosphorylation in transfected cells. a, b,
Cells were cotransfectedwith the cDNA corresponding to D5 (1.5g) and Gal2 (2g) receptors (a) or to D1 (1g) and Gal2 (2g)
receptors (b). Cells were treated for 5 min with the indicated concentrations of galanin in the absence (circles) or in the presence
(triangles) of 50 nM (a) or 70 nM (b) of SKF 81297. The immunoreactive bands from four independent experimentswere quantified
and the values represent the mean SEM of phosphorylation (arbitrary units) minus the basal levels found in untreated cells.
Figure 6. D1-like receptor antagonist-mediated blockade of galanin-induced ERK1/2 phosphorylation in cells expressing D1-
like and Gal1 receptors. a, Cells were transfected with the cDNA corresponding to D5 (1.5g, black), D1 (1.2g, white) or Gal1
receptors (2g, gray) and were stimulated with the D1-like receptor agonist SKF 81297 (70 nM) or with galanin (100 nM) in the
presence or absence of the D1-like receptor antagonist SCH 23390 (10M) or the Gal1 receptor antagonist M40 (10M); ***p
0.001 [significantly different compared to the effect of SKF 81297 alone (black andwhite columns) or to the effect of galanin alone
(gray columns); one-wayANOVAwithBonferroni’s correction].b, c, Cells cotransfectedwith the cDNAcorresponding toD5 (1.3g)
andGal1 receptors (1.8g) (b) or toD1 (1g) andGal1 (1.8g) receptors (c)were treatedwith SCH23390 (10M),M40 (10M),
SKF 81297 (70nM), or galanin (100nM) aloneor in combination; ***p0.001 [significantly different compared to the effect of SKF
81297 alone (in cells treatedwith SKF 81297) or to the effect of galanin alone (in cells treatedwith galanin); one-way ANOVAwith
Bonferroni’s correction]. In all cases, cells were treated for 5 min with the indicated concentrations of agonists and 20 min before
the addition of agonistswith the indicated concentrations of antagonists. The inmunoreactive bands from four to five experiments
were quantified, and the values represent themean SEMof the percentage of phosphorylation relative to the basal levels found
in untreated cells (100%).
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aptosomal preparations, nor the D1-like receptor agonist SKF
38393 (20–100 nM) significantly (p  0.05; n  3–6) affected
K-induced ACh release, as assessed by modifications of the
S2/S1 ratio after addition of the agonists before S2. However,
prior addition of SKF 38393 (20 nM; added before S1 and being
present during S1 and S2) triggered an excitatory effect (p 0.05;
n 6) of galanin (30 nM; only added before S2) on evoked ACh
release (Fig. 8a). On the other hand, no significant functional
effects where observed with the reverse protocol, since adding
galanin (30 nM) before S1 did not influence the absence of effect
of SKF 38393 (20 nM, only added before S2) (Fig. 8b). These
results nicely correlate with the functional results obtained in
cells expressingD1 orD5 andGal1 receptors, showing the selective
enhancement of Gal1 but not Gal2 receptor-mediatedMAPK sig-
naling by a D1-like receptor agonist. Therefore, the results
strongly suggest thatD1–Gal1 orD5–Gal1 receptor heteromers are
present in ventral hippocampal cholinergic terminals where they
modulate ACh release.
The role of D1-like and Gal1 receptor coactivation on rat
ventral hippocampus synaptic transmission
To identify whether D1-like–Gal1 receptor interactions affect ex-
citatory synaptic transmission in the hippocampus, we evaluated
the effect of galanin on EPSPs in hippocampal slices (Fig. 9a) in
the absence or presence of the dopaminergic receptor agonist
SKF 38393. As illustrated in Figure 9, b and e, when galanin (30
nM) was applied alone to ventral hippocampal slices, there was a
statistically significant (p 0.05; n 9) inhibition (21 2.6%)
of the slope of fEPSP. On the other hand, SKF 38393 (20 nM) was
virtually devoid of effect (n 7) on the slope of fEPSP (Fig. 9c,e).
However, in the presence of SKF 38393, the effect of galanin was
reversed and it produced a significant increase of 15.4  2.4%
(p 0.05; n 8) in the slope of fEPSPs (Fig. 9d,f). These results
indicate a synergistic effect when both D1-like and Gal1 receptors
are costimulated by agonists and match those results obtained in
synaptosomal preparations when measuring ACh release and
those results obtained in transfected cells and in ventral hip-
pocampal slices while measuring EPK phosphorylation. More-
over, blockade ofD1-like receptors with SCH23390 (1M; added
30 min before SKF 38393) completely counteracted the effect of
SKF 38393 (Fig. 9d,f). Indeed, in the presence of SCH 23390 (1
M) and SKF 38393 (20 nM), galanin (30 nM) decreased (p 0.05;
n  6) the slope of fEPSPs by 21.2  3.4% (Fig. 9d), an effect
similar to that observed when galanin was applied to the slices
alone (Fig. 9b,f).
Based on our results on the modulation of ACh release from
isolated nerve terminals (see Fig. 8) and previous evidence that
dopamine and galanin receptors regulate septohippocampal cho-
linergic neurotransmission, we hypothesized that the cross talk
between galanin and dopamine receptors involved in the modu-
lation of hippocampal excitatory transmission resulted from
modulation of cholinergic neurotransmission. To test this hy-
pothesis, we used the muscarinic cholinergic receptor antagonist
atropine (5 M), which by itself did not significantly modify
fEPSPwhen applied to ventral hippocampal slices (Fig. 10b). The
application of SKF 38393 (20 nM) after previous application (at
least 30 min before) of atropine also did not significantly affect
synaptic transmission (Fig. 10b). However, when galanin was
added, a significant inhibition (p  0.05; n  6) of the slope of
fEPSP was observed (Fig. 10a,b). This inhibition (21 5%) was
similar to the inhibition obtainedwhen galaninwas applied in the
absence of any drug (18  0.9%) (Fig. 8a,d), demonstrating a
cholinergic-independent depressant effect of galanin, but a
cholinergic-dependent facilitatory action of galanin that requires
D1-like receptor activation. These results suggest that D1-like–
Gal1 receptor heteromers localized in cholinergic terminals influ-
ence excitatory synaptic transmission in the ventral hippocampus.
Finally, we performed fEPSP measurements using slices of dorsal
hippocampus. Application of galanin (30 nM) to dorsal hippocam-
pal slices had no significant effect on fEPSP slope (Fig. 11a). Appli-
cation of SKF 38393 (20 nM) was also devoid of any effect on fEPSP
slope (Fig. 11b). Furthermore, previous addition of SKF 38393 (20
nM; 30 min before) did not trigger any effect of galanin on fEPSPs
(Fig. 11c,d). These results agree with the selective existence of D1-
like–Gal1 receptor interactions in the ventral versus the dorsal
hippocampus, as indicated by the ERK1/2 phosphorylation
experiments in hippocampal slices.
Figure 7. D1-like receptor antagonist-mediated blockade of galanin-induced ERK1/2 phos-
phorylation in rat hippocampal slices. Slices fromdorsal (black) or ventral (white) hippocampus
were treated for 10minwithmedium, SCH 23390 (10M), orM40 (10M) before the addition
of galanin (300 nM) and an additional incubation period of 10 min. The inmunoreactive bands
from four slices from two different animals were quantified and the values represent the
mean SEM of the percentage of phosphorylation relative to the basal levels found in un-
treated slices (100%). *p 0.05; **p 0.01 (significantly different compared to the effect of
galanin alone; one-way ANOVA with Bonferroni’s correction).
Figure 8. Effect of a D1-like receptor agonist and galanin on K
-induced [ 3H]ACh release
fromventral hippocampal synaptosomes.a, Dopamine receptorswere activated (right column)
by preincubation with the agonist SKF 38393 before addition of galanin. b, Galanin receptors
were activated (right column) by preincubation with galanin before addition of SKF 38393.
Ordinates represent the S2/S1 ratios as percentage of the control value in the sameexperiments
(seeMaterials andMethods). Drug conditions during S1 and S2 are indicated below each bar. In
the ordinates, 100% represents the S2/S1 ratio in the absence of the test drug, i.e., in the
absence of galanin (a) or in the absence of SKF 38393 (b), using the same synaptosomal batch.
An S2/S1 ratio close to 100% represents, therefore, absence of effect of the test drug (galanin in
a or SKF 38393 in b). Values are mean SEM (n 3–6). In a, 100% corresponds to 0.76
0.046, and in b it corresponds to 0.70 0.029. The presence of SKF 38393 (a) or of galanin (b)
during S1 and S2 did not significantly affect S2/S1 ratios compared with those obtained in the
absence of any drug. *p 0.05; NS, p 0.05 (Student’s t test).
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Discussion
By using amultidisciplinary approach, we
provide several important mechanistic
and functional insights into the role of
galanin and dopamine on regulation of
ACh release in the hippocampus. We
show, for the first time, that dopamine
D1-like receptors form heteromers with
Gal1 but not Gal2 receptors in transfected
cells and in rat ventral hippocampus.
Within the D1–Gal1 andD5–Gal1 receptor
heteromers, dopamine receptor activa-
tion and blockade potentiate and coun-
teract, respectively, MAPK activation
induced by stimulation of Gal1 receptors,
whereas Gal1 receptor ligands do not
modify D1-like receptor-mediatedMAPK
activation. We also demonstrate that do-
pamine and galanin work in concert to
modulate cholinergic neurotransmission
in the ventral hippocampus and that this
modulation could occur via heteromers
between D1 or D5 receptors and Gal1
receptors.
Using an in vitro cell culture system,we
demonstrated by BRET the ability of both
D1 and D5 receptors to form heteromers
with Gal1 but not Gal2 receptors. This is
not surprising if we consider that these
two galanin receptors have relatively low
amino acid similarity (Branchek et al.,
2000). Although bothD1 andD5 receptors
were able to compete for their heteromer-
ization with the Gal1 receptor, only the C
terminus of the D5 receptor pulled down
the whole Gal1 receptor from membrane
preparations of transfected cells. On the
one hand, these results suggest that addi-
tional regions outside of the C terminus
play a role in forming heteromers and that
there are differences between D5 and D1
receptors in the regions involved in het-
eromerizationwithGal1 receptors. On the
other hand, our results strongly suggest
that D1 and D5 receptors compete for the
same region of Gal1 receptors.
One of themain challenges in the study
of membrane protein complexes is their
identification in native tissues. Solubility
issues and unreliable antibodies make
coimmunoprecipitation experiments diffi-
cult to interpret, and current spectroscopic approaches, with
few exceptions, lack the resolution for an in situ approach at
the single-molecule level. These limitations thus require indi-
rect approaches to validate the presence of such membrane
complexes, such as the determination of a biochemical prop-
erty of the receptor heteromer, which can be used as a “bio-
chemical fingerprint” (Ferre´ et al., 2009). The cross-antagonism
inwhich aD1-like receptor antagonist is able to block the effect of
a Gal1 receptor agonist is very difficult to explain by amechanism
not involving receptor heteromerization, taking into account
that an antagonist does not induce intracellular signaling. This
cross-antagonism was therefore used as a “biochemical finger-
print” of the D1-like–Gal1 receptor heteromer. Using these crite-
ria andmeasuringMAPK activation as an endpoint, we were able
to identify D1-like–Gal1 receptor heteromers in the ventral, but
not the dorsal, hippocampus.
Although the existence of Gal1 receptors on septohippocampal
cholinergic neurons has been questioned previously (Miller et al.,
1997), ourobservationsof the samequalitative cross talk in signaling
in synaptosomal preparations as in cells expressingD1-like andGal1
receptors strongly suggests that functionalGal1 receptors arepresent
in cholinergic terminals of the ventral hippocampus. As mentioned
above, in transfected cells, D1-like receptor stimulation potentiates
Figure 9. Effect of coactivation of D1-like and galanin receptors on galanin-mediated modulation of synaptic transmission in
the ventral hippocampus. a, Schematic representation of a transverse hippocampal slice with the electrode configuration used to
record fEPSPs in the CA1 apical dendritic layer (stratum radiatum) evoked by electric stimulation (S0) of the Schaffer fibers. b,
Averaged time courses of changes in fEPSP slope induced by application of 30 nMgalanin alone. c, Averaged time course of changes
in fEPSP slope induced by application of 20 nM SKF 38393 alone. d, Averaged time courses of the effect of galanin (30 nM) in the
presence of theD1-like receptor agonist SKF 38393 (20nM;F) or in the presence of both SKF 38393 (10nM) and theD1-like receptor
antagonist SCH23390 (1M;E). SKF 38393was applied at least 30min before galanin application, and SCH23390was applied 30
min before SKF 38393 application. e, Recordings obtained from representative experiments, where each trace is the average of
eight consecutive responses obtained in absence (1) andpresence (2) of galanin (30nM; left), in absence (3) andpresence (4) of SKF
38393 (20nM;middle), and in absence (5) andpresence (6) of galanin (30nM)when the slicewas incubatedwith SKF 38393 (20nM;
right) are shown D1-like; each trace is composed of the stimulus artifact followed by the presynaptic volley and the fEPSP.
Superimposed recordings were obtained from the same slice at the time points indicated in b–d. Note the inhibitory effect of
galanin in b (absence of SKF 38393) and facilitatory effect in d (presence of SKF 38393). f, Comparison between the averaged
effects of galanin on hippocampal synaptic transmission in presence of SKF 38393 and in the presence of both SKF 38393 and SCH
23390. The ordinates show the percent change of fEPSP slope induced by galanin (30 nM) 50–60 min after its application to
hippocampal slices not treatedor treatedwith SKF38393and treatedwithboth SKF38393andSCH23390, as indicatedbeloweach
bar. , p 0.05 (one-way ANOVA with Bonferroni’s correction) as compared with absence of galanin in the same slices;, p
0.05 (one-way ANOVA with the Bonferroni’s correction) as compared with galanin alone. All values are mean SEM [100%,
averaged fEPSP slopes at times10 to 0: d,0.69 0.073 mV/ms, n 8 (F);0.66 0.103 mV/ms, n 6 (E); b,
0.69 0.023 mV/ms, n 9; c,0.64 0.041 mV/ms, n 7].
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the effects ofGal1 but notGal2 receptor activation, butGal1 receptor
stimulation does not modify D1-like receptor-mediated signal-
ing. In hippocampal synaptosomal preparations at nanomolar
concentrations, neither galanin nor a D1-like receptor agonist
produced anymodification of K-induced
ACh release. Nevertheless, previous activa-
tion of D1-like receptors triggered a facili-
tatoryeffectof galanin.Alsoas in transfected
cells, galanin did not modify the lack of ef-
fect of a D1-like receptor agonist. Since D5
predominates over D1 receptors in the hip-
pocampus (Ciliax et al., 2000), and D5 re-
ceptors have been shown previously to be
involved in themodulation of hippocampal
ACh release (Hersi et al., 2000; Laplante et
al., 2004b), D5 is probably the main D1-like
receptor subtype forming heteromers with
Gal1 receptors in cholinergic terminals of
the ventral hippocampus.
In previous studies, galanin generally
showed an inhibitory effect on hippocam-
pal cholinergic neurotransmission (Fi-
sone et al., 1987; O¨gren et al., 1998;
Laplante et al., 2004a). However, most of
these studies were performed with in vivo
microdialysis techniques using much
higher (micromolar) concentrations of
galanin than in the present experiments
(O¨gren et al., 1998; Laplante et al., 2004a)
and with artificially increased extracellu-
lar concentrations of ACh because of the
addition of acetylcholinesterase inhibitors
in the perfusion medium. The use of ace-
tylcholinesterase inhibitors in the dialysis
mediumhas raised concerns about the pos-
sibility of not only quantitative but also
qualitative artifactual results (DeBoer and
Abercrombie, 1996; Acquas and Fibiger,
1998). At the level of the Shaffer–CA1gluta-
matergic synapses of the ventral hippocam-
pus, a low (nanomolar) concentration of
galaninwas inhibitory providing that dopa-
mine receptors were not activated. This re-
sult is in accordance with the expression of
Gal1 receptors in theCA1 area of the ventral
hippocampus (O’Donnell et al., 1999). In
fact, we found galanin to be completely in-
effective in the dorsal hippocampus. This
cholinergic-independent depressant effect
of galanin could be related to its ability to
decrease neuronal hippocampal glutama-
tergic neurotransmission (Zini et al., 1993;
Mazarati et al., 2000).Also, galaninhas been
reported to inhibit LTP in the Shaffer–CA1
glutamatergic synapses (Sakurai et al.,
1996). The D1-like receptor agonist, which
was ineffective when administered alone,
turnedan inhibitory effectof galanin intoan
excitatory effect, and this interaction de-
pended on cholinergic neurotransmission,
since it was completely blocked by amusca-
rinic ACh receptor antagonist. From our
results from ventral hippocampal synapto-
somal preparations and slices, a model of the role of galanin in the
Shaffer–CA1 synapses of the ventral hippocampus can be proposed:
an isolated increase in the activity of the septohippocampal cholin-
ergic input produces a modest release of ACh and galanin. This
Figure10. Effectofmuscarinicreceptorblockadeonthedopamine-dependentgalanin-mediatedmodulationofsynaptictransmission
in the ventral hippocampus. a, Top, Averaged time courses of the effect of galanin (30 nM) in the presence of both the D1-like receptor
agonist SKF 38393 (20 nM) and themuscarinic acetylcholine receptor antagonist atropine (5M). SKF 38393was applied at least 60min
beforegalanin, andatropinewasapplied30minbefore SKF38393.Bottom, Tracesobtainedwitha representative experiment; each trace
is the average of eight consecutive responses obtained immediately before (1) andduring (2) galanin application, and is composed of the
stimulusartifactfollowedbythepresynapticvolleyandthefEPSP.b,Comparisonbetweentheaveragedeffectsofgalanin(30nMfor50–60
min) in the absence of drugs and in the presence of both SKF 38393 and atropine. The averaged effects of atropine andboth atropine and
SKF38393arealsoshown;,p0.05(Student’s t test)comparedwithabsenceofgalanin inthesameslices;,p0.05(Student’s t test)
comparedwithbothatropine andSKF38393present in the same slices. All values are shownas themeanSEM(100%, averaged fEPSP
slopes at times10–0:a,0.60 0.037mV/ms;n 6).
Figure 11. Lack of effect of galanin on synaptic transmission in the dorsal hippocampus.a,b, Averaged time course of changes
in fEPSP slope induced by application of 30 nM galanin (a) or 20mM SKF 38393 (b). c, Averaged time courses of the effect of galanin
(30 nM) in the presence of the D1-like receptor agonist SKF 38393 (20 nM). SKF 38393 was applied at least 30 min before galanin;
ordinates showthepercent changeof fEPSP slope inducedbygalanin (30nM)50–60minafter its application tohippocampal slices
not treated and treated with SKF 38393, as indicated below each bar. All values are shown as the mean SEM (100%, averaged
fEPSP slopes at times10–0: a,0.55 0.070mV/ms, n 5; b,0.58 0.048mV/ms, n 3; c,0.55 0.064mV/ms,
n 3). d, Comparison between the averaged effects of galanin in the presence and absence of SKF 38393.
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modest releaseof galaninwould, nevertheless, be sufficient to inhibit
the excitability of glutamatergic synapses by actingonpresynaptic or
postsynaptic galanin receptors. However, with a concomitant in-
crease in the activity of the ventral tegmental area (VTA)–hip-
pocampal dopaminergic input, coactivation of D1-like and galanin
receptors localized in cholinergic terminals induces a strong release
of ACh, which overcomes the inhibitory role of galanin and leads to
increased excitability of the glutamatergic synapses.
The interactions reported here occur in the ventral but not in
the dorsal hippocampus. These two hippocampal areas have dif-
ferential efferent connections with the rest of the brain, such that
the dorsal hippocampus is primarily connected with the neocor-
tex, whereas the ventral hippocampus is connected to subcortical
structures, such as the hypothalamus and the amygdala (Naber
and Witter, 1998). Since both the amygdala and the hypothala-
mus control the activity of the hypothalamus–pituitary–adrenal
axis, it is therefore not a surprise that a major function of the
ventral hippocampus is the processing of information related to
emotion-related behaviors, as increasing evidence now indicates
(Segal et al., 2010). Interestingly, injection of acetylcholine into
the ventral, but not the dorsal, hippocampus, reduces anxiety
(Degroot and Treit, 2004). One can therefore speculate that the
cholinergic-dependent facilitatory action of galanin on excitatory
Schaffer–CA1 synapses (a last relay of the excitatory output of the
hippocampus) may influence the control of anxiety and emo-
tional memory.
Altogether, our results strongly suggest that D1-like–Gal1 re-
ceptor heteromers that are localized in cholinergic nerve termi-
nals play an important role in the modulation of cholinergic
neurotransmission in the ventral hippocampus. Receptor hetero-
mers are becoming the focus of extensive research in the field of
GPCRs, and we are just starting to understand the mechanisms
involved in heteromerization and its functional meaning (Bu-
lenger et al., 2005; Ferre´ et al., 2007; Dalrymple et al., 2008; Mil-
ligan, 2009; Rozenfeld and Devi, 2010). The present study
provides a clear example of a receptor heteromer acting as a pro-
cessor that integrates signals of different neurotransmitters and
modulates cell signaling and neuronal function (Ferre´ et al.,
2007). Since receptor heteromers are increasingly being consid-
ered as pharmacological targets (George et al., 2002; Ferre´ et al.,
2010), D1–Gal1 and D5–Gal1 receptor heteromers could be con-
sidered targets for drugs useful in Alzheimer’s disease, in view of
the involvement of the septohippocampal cholinergic system in
this disease (O¨gren et al., 1998; Mitsukawa et al., 2008). Impor-
tantly, D1, D5, and Gal1 receptors are also colocalized in brain
areas other than the hippocampus, such as the mesencephalic
dopaminergic nuclei substantia nigra and theVTA (Schilstro¨m et
al., 2006; Picciotto, 2008). If D1-like–Gal1 receptor heteromers
are also present in the mesencephalic dopaminergic cells, they
could be targets for the treatment of dopamine-related neuropsy-
chiatric disorders, including drug addiction. Finally, the ability of
galanin receptors to heteromerize with other GPCRs in other
regions of the CNS could explain pharmacological findings that
have so far been difficult to explain, such as the well-known bi-
phasic dose-dependent effect of galanin on nociception (Xu et al.,
2008).
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